Obalon Therapeutics Inc. (NASDAQ: OBLN) is 190.00% higher on its value in year-to-date trading and has touched a low of $0.62 and a high of $10.77 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The OBLN stock was last observed hovering at around $4.33 in the last trading session, with the day’s gains setting it 0.02% off its average median price target of $6.15 for the next 12 months. It is also 29.27% off the consensus price target high of $6.15 offered by 1 analysts, but current levels are 29.27% higher than the price target low of $6.15 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $4.35, the stock is -7.35% and 43.49% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.22 million and changing 0.46% at the moment leaves the stock 209.09% off its SMA200. OBLN registered 136.41% gain for a year compared to 6-month gain of 424.10%. The firm has a 50-day simple moving average (SMA 50) of $3.7621 and a 200-day simple moving average (SMA200) of $1.6860.
The stock witnessed a -16.18% loss in the last 1 month and extending the period to 3 months gives it a 362.18%, and is -9.38% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.08% over the week and 14.13% over the month.
Obalon Therapeutics Inc. (OBLN) has around 34 employees, a market worth around $33.76M and $2.30M in sales. Distance from 52-week low is 601.61% and -59.61% from its 52-week high. The company has generated returns on investments over the last 12 months (-147.00%).
Obalon Therapeutics Inc. (OBLN) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Obalon Therapeutics Inc. (OBLN) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Obalon Therapeutics Inc. is expected to release its quarterly report on 05/13/2021 and quarterly earnings per share for the current quarter are estimated at -$0.06.The EPS is expected to grow by 74.40% this year, but quarterly earnings will post -54.30% year-over-year.
Obalon Therapeutics Inc. (OBLN) Top Institutional Holders
The shares outstanding are 7.73M, and float is at 7.47M with Short Float at 10.75%.
The top institutional shareholder in the company is Vanguard Extended Market Index Fund with over 43043.0 shares valued at $39186.0. The investor’s holdings represent 0.55% of the OBLN Shares outstanding. As of Sep 29, 2020, the second largest holder is Bridgeway Funds Inc-Ultra Small Company Market Fund with 33000.0 shares valued at $30043.0 to account for 0.42% of the shares outstanding. The other top investors are Fidelity Extended Market Index Fund which holds 5779.0 shares representing 0.07% and valued at over $5261.0, while Fidelity NASDAQ Composite Index Fund holds 0.06% of the shares totaling 4977.0 with a market value of $4531.0.
Obalon Therapeutics Inc. (OBLN) Insider Activity
A total of 0 insider transactions have happened at Obalon Therapeutics Inc. (OBLN) in the last six months, with sales accounting for 0 and purchases happening 0 times.